Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
Daiichi Sankyo saw its group sales in FY2018 slip 3.2% year on year to 929.7 billion yen as big growth from its anticoagulant hopeful Lixiana (edoxaban) failed to offset the impact of generic inroads into its flagship hypertension drug Olmetec…
To read the full story
Related Article
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Daiichi Sankyo Logs Double-Digit Growth in Q1 as Olmetec Cliff Tails Off; Profit Zooms on AZ Deal, Asset Sale
August 1, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
BUSINESS
- J-Pharma Inks Licensing Term Sheet for LAT1 Inhibitor JPH034
September 28, 2026
- Maruho, BMS Forge Japan Marketing Alliance for Sotyktu
September 28, 2026
- European Pharma Chairs Urge Policy Shift on Innovative Drug Investment
September 25, 2026
- SymBio Inks Exclusive HHS License for BCV in Multiple Sclerosis
September 25, 2026
- Tokyo Court Blocks Toho’s Poison Pill Move; Company to Appeal
September 25, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…